NCT02914639View on ClinicalTrials.gov

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 5, 2016

Primary Completion Date

June 26, 2017

Study Completion Date

June 26, 2017

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

SF0166 Topical Ophthalmic Solution

Trial Locations (12)

33126

Retina Macula Specialists of Miami, LLC, Miami

33880

Center for Retina and Macular Disease, Winter Haven

47150

John Kenyon Eye Institute, New Albany

57701

Black Hills Regional Eye Institute, Rapid City

76104

Texas Retina Associates, Fort Worth

78705

Retina Research Center, PLLC, Austin

79606

West Texas Retina Consultants, Abilene

85014

Retinal Research Institute LLC, Phoenix

92861

Retina Consultants of Orange County, Fullerton

94040

Northern California Retina Vitreous Associates Medical Group, Inc, Mountain View

99204

Spokane Eye Clinical Research, Spokane

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

OcuTerra Therapeutics, Inc.

INDUSTRY

NCT02914639 - Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter